Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B7EK | ISIN: JP3431300007 | Ticker-Symbol: JSS
München
05.06.25 | 08:06
5,950 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
JAPAN
1-Jahres-Chart
NXERA PHARMA CO LTD Chart 1 Jahr
5-Tage-Chart
NXERA PHARMA CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
5,7005,95012:02

Aktuelle News zur NXERA PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiNxera Hits Important Milestone in Diabetes Drug Partnership with Eli Lilly9
DiNxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-111756867Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that its partner, Neurocrine Biosciences ("Neurocrine") has dosed the first...
► Artikel lesen
MoNxera Pharma Reaches Key Milestone In Lilly Partnership For Diabetes & Metabolic Disease Research433INDIANAPOLIS (dpa-AFX) - Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY)...
► Artikel lesen
MoNxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases110Tokyo, Japan and Cambridge, UK, 2 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration...
► Artikel lesen
02.05.Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025120Tokyo, Japan and Cambridge, UK, 2 May 2025 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter...
► Artikel lesen
01.05.Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia141NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineFor more information...
► Artikel lesen
NXERA PHARMA Aktie jetzt für 0€ handeln
01.05.Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations1
03.04.Nxera Pharma appoints AstraZeneca alum as inaugural commercial chief3
01.04.Nxera Pharma Announces Appointments to its Executive Leadership Team1
25.03.Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder274Tokyo, Japan and Cambridge, UK, 25 March 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a...
► Artikel lesen
28.02.Nxera sells APAC license to lupus drug to Viatris for $10M upfront32
28.02.Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan1
28.02.Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris30
14.02.Nxera Pharma Proposes Changes to its Board of Directors1
14.02.Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024341Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) provides an update on operational activities and reports its consolidated results for...
► Artikel lesen
07.02.Singtel's Nxera DCT bags $643m green loan for new data centre in Tuas2
23.01.Nxera Pharma Webinar Presentation for FY2024 Financial Results3
14.01.Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio11
19.12.24Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Adults with Insomnia14
05.12.24Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea181Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomniaQUVIVIQ (daridorexant) 25 and 50 mg was recently approved and is expected...
► Artikel lesen
Seite:  Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1